|
Operational Highlights |
Second Quarter |
Year-to-Date |
|||||
|
2022 |
2023 |
2022 |
2023 |
||||
|
Systemwide Sales Growth(1) |
|||||||
|
U.S. |
3.5 % |
6.1 % |
3.0 % |
7.3 % |
|||
|
International(2) |
22.7 % |
12.7 % |
21.1 % |
16.6 % |
|||
|
Global |
5.6 % |
6.9 % |
4.9 % |
8.4 % |
|||
|
Same-Restaurant Sales Growth(1) |
|||||||
|
U.S. |
2.3 % |
4.9 % |
1.7 % |
6.0 % |
|||
|
International(2) |
15.2 % |
7.2 % |
14.7 % |
10.3 % |
|||
|
Global |
3.7 % |
5.1 % |
3.1 % |
6.5 % |
|||
|
Systemwide Sales (In US$ Millions)(3) |
|||||||
|
U.S. |
$3,001 |
$3,185 |
$5,713 |
$6,129 |
|||
|
International(2) |
$419 |
$461 |
$779 |
$879 |
|||
|
Global |
$3,420 |
$3,646 |
$6,491 |
$7,009 |
|||
|
Restaurant Openings |
|||||||
|
U.S. – Total / Net |
29 / 14 |
19 / 4 |
74 / 45 |
39 / (1) |
|||
|
International – Total / Net |
18 / 10 |
22 / 16 |
66 / 46 |
41 / 21 |
|||
|
Global – Total / Net |
47 / 24 |
41 / 20 |
140 / 91 |
80 / 20 |
|||
|
Global Reimaging Completion Percentage |
75 % |
82 % |
|||||
Maxim Group Downgrades Amryt Pharma to Hold
Maxim Group analyst Jason McCarthy downgrades Amryt Pharma (NASDAQ:AMYT) from Buy to Hold.